

9<sup>th</sup> Canadian Kidney Cancer Forum

# Canadian Kidney Cancer Forum

FINAL PROGRAM

KCRNC

KIDNEY CANCER RESEARCH  
NETWORK OF CANADA

RRCRC

RÉSEAU DE RECHERCHE SUR LE  
CANCER DU REIN DU CANADA



#CKCF18

February 22-24, 2018

Kingbridge Centre, King City, ON

# 9<sup>th</sup> Canadian Kidney Cancer Forum

## Objectives for Forum 2018

The primary meeting objectives are to:

- Increase knowledge of recent developments in the management of renal cell carcinoma;
- Discuss and stimulate new research in kidney cancer nationally;
- Raise awareness of ongoing research in kidney cancer in Canada;
- Identify future initiatives and projects for the KCRNC;
- Explore ideas to ensure the progress and sustainability of KCRNC;
- Examine recent clinical trial data.

**THURSDAY, FEBRUARY 22, 2018**

1500 - 1800    [Arrival & Registration - Front Lobby](#)

1830 - 1930    [Buffet Dinner in Connections Restaurant](#)

### SESSION I - IMMUNOTHERAPY UPDATES

[Session Room: Grand Room AB](#)

1930 - 1935    [Welcome and Introduction of Program Co-Chairs](#)  
Anil Kapoor

1935 - 1945    [Welcome: Overview Of Program, Speakers  
and Meeting Objectives](#)  
Simon Tanguay, Lori Wood

Introduction/Moderators: Henry Conter, Jean-Baptiste Lattouf

1945 - 2005    [Immune Checkpoint Blockers:  
Today and Tomorrow](#)  
Manuela Schmidinger

2005 - 2010    [Discussion and Q & A](#)

February 22-24, 2018 • Kingbridge Centre, King City, ON

# 9<sup>th</sup> Canadian Kidney Cancer Forum

- 2010 - 2030    Decoding the Discussion Between the Immune System and Tumors: A Translator Perspective  
Réjean Lapointe
- 2030 - 2035    Discussion and Q & A
- 2045 - 2300    [Networking Opportunity with Colleagues in Bridges](#)  
(all welcome)

## FRIDAY, FEBRUARY 23, 2018

- 0700 - 0800    [Buffet Breakfast in Connections Restaurant](#)
- 0700 - 0800    CKCis Operations Committee Meeting  
(CKCis site investigators & support staff)  
[Breakfast Served in Meeting Room](#)  
Room 20

## SESSION II - CURRENT RESEARCH IN CANADA

[Session Room: Grand Room AB](#)

Introduction/Moderators: Stephen Pautler, François Patenaude

- 0800 - 0830    CKCis Update Report: Data, Recent Publications and Ongoing Research  
Naveen Basappa, Rodney Breau
- 0830 - 0850    Renal TRACERx: Deterministic Evolutionary Trajectories Govern Primary Tumour Growth  
Samra Turajlic
- 0850 - 0855    Discussion and Q & A

Introduction/Moderators: Scott North, Laurie Ailles

- 0855 - 0935    Highlights in Kidney Cancer Research in Canada
- Emily Wong (McMaster): Renal Cell Carcinoma in the Canadian Indigenous Population
- Sandra Turcotte (Université de Moncton): Overexpression of MIR-2355 Revealed SUSD4 as Predicted Target in VHL-Inactivated Renal Cell Carcinoma

February 22-24, 2018 • Kingbridge Centre, King City, ON

# 9<sup>th</sup> Canadian Kidney Cancer Forum

Kristen McAlpine (University of Ottawa): Development of a Patient Decision Aid for Complex, Localized Renal Masses

Jan Rudzinski (University of Alberta): Exploiting Novel Therapeutic Targets to Block Metastasis of Clear Cell Renal Cell Carcinoma

0935 - 0955 **Immune Checkpoint Blockades in the Clinic: Unanswered Questions, Optimizing Use, and Patterns of Response**  
Toni Choueiri

0955 - 1000 **Discussion and Q & A**

1000 - 1015 **Health Break in North Wing Main Foyer**  
**Exhibitor and Poster Viewing**

**Introduction/Moderators:** Neil Reaume, Luke Lavallée

1015 - 1045 **Spotlight on KCRNC-Research Trainees**

Keith Lawson (University of Toronto): Identification and Translation of Novel Kidney Cancer Immunotherapeutic Targets Through Genetic Screens Using the CRISPR-Cas9 System

Rola Saleeb (St. Michael's Hospital) Understanding the Attributes of Papillary Renal Cell Carcinoma Subtypes: Molecular Analysis, Biomarker Discovery and Implications to Therapy

Matthew Lowerison (University of Western Ontario): Genomics Analysis with Functional Imaging of RCC Patient Derived Xenografts (PDXs) to Determine If There Are Key Genetic Mutations That Are Responsible For a Drug Resistant Phenotype.

1045 - 1125 **Clinical Trials Update, Opportunities, and Ongoing Projects in Canada**  
Christian Kollmannsberger

February 22-24, 2018 • Kingbridge Centre, King City, ON

# 9<sup>th</sup> Canadian Kidney Cancer Forum

## LATE BREAKING CANADIAN PROJECTS

Session Room: Grand Room AB

Introduction/Moderators: Andrew Matthew, Alan So

- 1125 - 1140 Results from Renal Hypothermia During Partial Nephrectomy  
Ilias Cagiannos, Rodney Breau
- 1140 - 1155 2017 CUA Follow-Up Guidelines for Resected RCC  
Wes Kassouf
- 1155 - 1210 Kidney Cancer Canada Updates  
Stephen Andrew, Andrew Weller
- 1210 - 1215 Discussion and Q & A
- 1215 - 1315 Buffet Lunch in Connections Restaurant  
Group Photo

## SESSION III: CLINICAL AND BIOLOGICAL GENETICS and BIOMARKERS

Session Room: Grand Room AB

Introduction/Moderators: Ricardo Rendon, Aly-Khan Lalani

- 1315 - 1335 Contemporary Role of Cytoreductive Nephrectomy  
Stephen Boorjian
- 1335 - 1340 Discussion and Q & A
- 1340 - 1400 Tracking Renal Cancer Evolution Reveals Constrained Routes to Metastases  
Samra Turajlic
- 1400 - 1405 Discussion and Q & A

Introduction/Moderators: Normand Blais, George Yousef

- 1405 - 1425 Precision Medicine from the Renal Cancer Genome  
Yasser Riazalhosseini
- 1425 - 1430 Discussion and Q & A

February 22-24, 2018 • Kingbridge Centre, King City, ON

# 9<sup>th</sup> Canadian Kidney Cancer Forum

- 1430 - 1450 Emerging Biomarkers of Immune Checkpoint Markers in RCC  
Toni Choueiri
- 1450 - 1455 Discussion and Q & A
- 1455 - 1510 [Health Break in North Wing Main Foyer](#)  
[Exhibitor and Poster Viewing](#)

## SESSION IV: BREAKOUT GROUPS

(Closed to Industry)

- 1515 - 1615 Group 1: Moving Forward with Clinical Genetics  
[Grand Room AB](#)  
Raymond Kim, Alan So
- Group 2: Understanding and Improving Survivorship Issues  
[Room 21](#)  
Jennifer Jones, Christina Canil
- Group 3: Optimizing/Personalizing RCC Therapy  
[Room 11](#)  
Georg Bjarnason, Sebastien Hotte
- Group 4: Advancing Diagnostic Abilities and Techniques in RCC  
[Room 20](#)  
Luke Lavallée, Pierre Karakiewicz
- 1615 - 1715 Break-Out: Consensus Guidelines  
Update of mRCC Consensus Guideline:  
Lead - Denis Soulières (invite only)  
[Room 11](#)
- 1730 - 1900 [Floor Hockey Tournament in the Sports Centre](#)
- 1930 - 2000 [Mix & Mingle: Cocktail Reception in North Foyer](#)
- 2000 [Banquet Dinner - Grand Room AB](#)  
[Discussion and Entertainment With Your KCRNC Hosts](#)
- 2130 - 2300 [Networking Opportunity with Colleagues in Bridges](#)  
(all welcome)

February 22-24, 2018 • Kingbridge Centre, King City, ON

# 9<sup>th</sup> Canadian Kidney Cancer Forum

**SATURDAY, FEBRUARY 24, 2018**

0730 - 0830 [Buffet Breakfast in Connections Restaurant](#)

0730 - 0830 Consensus Guideline  
Role of Cytoreductive Nephrectomy:  
Lead - Ricardo Rendon, Ross Mason  
(invite only) - [Room 11](#)  
[Breakfast Served in Meeting Room](#)

## **SESSION V: MOVING FORWARD**

[Session Room: Grand Room AB](#)

**Introduction/Moderators:** Michael Jewett, Ilias Cagiannos, Christine Collins

- 0830 - 0845 Grant Presenter 1 - Shaan Dudani  
Identifying Prognostic and Predictive Biomarkers in  
Metastatic Renal-Cell Carcinoma: An Exploratory Study  
of the International Metastatic Renal Cell Carcinoma  
Database Consortium (IMDC) Tissue Biorepository
- 0845 - 0900 Grant Presenter 2 - Jan Krzysztof Rudzinski  
The Preclinical Development of a Novel Formulation to  
Silence the Expression of Proteins Required for Renal Cell  
Carcinoma Metastasis
- 0900 - 0915 Grant Presenter 3 - Patrick Richard  
Surveillance of Complex Renal Cysts - The SoCRATiC  
Pilot Trial
- 0915 - 0930 Grant Presenter 4 - Ninadh D'costa  
Assessing Glioma-Protein Inhibition in Sunitinib-Resistance  
Using a Tissue-Engineered RCC Patient Derived  
3-Dimensional Model
- 0930 - 0945 Grant Presenter 5 - Bertrand Routy  
Immune-Potentiating Impact of the Gut Microbiome on  
Kidney Cancer Immune Infiltrate: A Novel Predictor of  
Immune Checkpoint Inhibitors Response
- 0945 - 0955 Discussion and Q & A

February 22-24, 2018 • Kingbridge Centre, King City, ON

# 9<sup>th</sup> Canadian Kidney Cancer Forum

Introduction/Moderator: Rodney Breau

- 0955 - 1015 Retroperitoneal Lymph Node Dissection For Renal Cell Carcinoma: Yes, No, or Sometimes?  
Stephen Boorjian
- 1015 - 1020 Discussion and Q & A
- 1020 - 1045 Exhibitor Health Break in North Wing Main Foyer  
Poster Viewing

Introduction/Moderators: Anil Kapoor, Simon Tanguay, Lori Wood

- 1045 - 1215 Group 1: Moving Forward with Clinical Genetics  
Raymond Kim, Alan So
- Group 2: Understanding and Improving Survivorship Issues  
Jennifer Jones, Christina Canil
- Group 3: Optimizing/Personalizing RCC therapy  
Georg Bjarnason, Sebastien Hotte
- Group 4: Advancing Diagnostic Abilities and Techniques in RCC  
Luke Lavallée, Pierre Karakewicz
- 1215 - 1230 Progress Report, Grant Winners and Future Discussion  
Anil Kapoor
- 1230 Boxed Lunch

This program is an accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, reviewed and approved by the Canadian Urological Association. Completion of this program enables participants to claim a maximum of 11 hours of credit.

SUPPORTED BY

KCRNC

KIDNEY CANCER RESEARCH  
NETWORK OF CANADA

RRCRC

RÉSEAU DE RECHERCHE SUR LE  
CANCER DU REIN DU CANADA



February 22-24, 2018 • Kingbridge Centre, King City, ON



# BIOGRAPHIES

## Meeting Co-Chairs



**Simon Tanguay**

Dr. Tanguay completed his residency training at McGill University in 1992 and a fellowship in Urologic Oncology at the University of Texas M.D. Anderson Cancer Center in 1995. Dr. Tanguay is currently Professor and Chairman of the division of Urology at McGill University and the M. Elhilali and D. Azrieli Chair in urologic sciences.

Dr. Tanguay was actively involved in the Quebec Urological Association where he served as President of the Continuous Medical Education from 2001 to 2004 and served as Treasurer of this Association. He was Co-Director of the clinical research unit within the Division of Urology at McGill University.

Dr. Tanguay served as a member of the executive committee of the Genito-Urinary group at the National Cancer Institute of Canada and as the Chair of the Canadian Kidney Cancer information system from 2009 to 2016. He was the General Secretary of the Société Internationale d'Urologie from 2011 to 2016 and now serves as President-Elect.



**Lori Wood**

Dr. Wood is a Medical Oncologist at the Queen Elizabeth II Health Sciences Centre, Halifax, NS, as well as a Professor in the Department of Medicine at Dalhousie University with a cross appointment in the Department of Urology. She completed her Medical Oncology training at the Cross Cancer Institute in Edmonton, Alberta and a Masters of Science in Epidemiology from the Harvard School of

Public Health. She spent two years on faculty at the MD Anderson Cancer Centre, in Houston, Texas, in the Department of Genitourinary Oncology before moving to Halifax in 2000.

Dr. Wood is a member of the CCTG (formerly NCIC) Genitourinary Disease Site Group and an active member of the Cancer Care Nova Scotia Genitourinary Cancer Site Team. She is involved in all levels of undergraduate, postgraduate and continuing medical education and serves as a mentor and supervisor for students and residents.

Dr. Wood is actively involved in phase II and III clinical trials in genitourinary malignancies with a specific clinical and research interest in renal cell carcinoma and testicular cancer.

# BIOGRAPHIES

## Canadian Faculty



### Réjean Lapointe

Réjean Lapointe is specialized in human tumor immunology since 1997. He got his basic training at Université Laval from 1987-1997 in microbiology and immuno-virology, and moved to the NIH in the group of Steven Rosenberg and Patrick Hwu while working on tumor immunology. He was recruited at Université de Montréal/CHUM/Institut du cancer de Montréal early in 2002, where he is now full professor. Objectives in the last 10 years were oriented at both fundamental and applied research to: study T and B lymphocyte biology, establishing a Cell therapy program, and a clinical Immuno-monitoring platform, study tumor-immune system interactions, find new tumor antigens, develop new vaccination systems and immunotherapies.

He is part of 2 FRQS Networks (cancer and cell therapy), the National Center of Excellence (NCE) on Biotherapeutics for Cancer Treatment (BioCanRx), and the immunotherapy network (iTNT) from the Terry Fox Research Institute. He manages the FRQS/CHUM Breast Cancer Bank and has established the clinical CHUM immune-monitoring platform (6 clinical trials with Pharma). He published over 60 articles in immunology, oncology and microbiology.




### Yasser Riazalhosseini

After undertaking post-doctoral studies on Cancer Genomics at the Deutsches Krebsforschungszentrum (DKFZ), Dr. Riazalhosseini joined the Department of Human Genetics at McGill as an Assistant Professor, and was appointed Group Head of the Cancer Genomics program at the McGill University and Genome Québec Innovation Centre (the McGill Genome Centre). His principal activity has been to initiate and lead a multidisciplinary, applied research program on genomics of renal cell carcinoma (RCC). Dr. Riazalhosseini's research is focused on understanding the causes of kidney cancer with the goals of obtaining better preventions and treatments. His research program uses systems biology approaches that combine genomics datasets involving sequences from hundreds of cancers coupled with detailed clinical data, and high-throughput functional studies. Contributing to his research goals, Dr. Riazalhosseini has a major role in the Cancer Genomics of the Kidney (CAGEKID) consortium where he has assumed joint responsibility for the data analysis and leads the down-stream validation of results.

# BIOGRAPHIES

## International Faculty



**Stephen Boorjian**

Dr. Stephen Boorjian is the Carl Rosen Professor of Urology, Vice Chair of Research for the Department of Urology, and the Director of the Urologic Oncology Fellowship at Mayo Clinic. He received his MD from Harvard Medical School, and was a resident in Urology at New York Presbyterian Hospital-Weill Cornell Medical Center. He subsequently completed a fellowship in Urologic Oncology at Mayo Clinic. Dr. Boorjian has co-authored over 300 manuscripts and book chapters, and has been recognized as “Teacher of the Year” in Urology by the Mayo Clinic Fellows’ Association (2012) and Young Urologist of the Year by the AUA (2014). He received the 2016 Young Investigator Award from the Society of Urologic Oncology. He is currently a member of the NCCN Guidelines Panels for Bladder Cancer and Penile Cancer, and previously served on the AUA Non-Muscle Invasive Bladder Cancer Guidelines Panel. He is also an Associate Editor for the journal *European Urology*.

---



**Toni Choueiri**

Dr. Toni Choueiri is the Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. He is the Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and President of the Medical Staff at Dana-Farber. He serves on the NCCN Kidney Cancer Panel and is Chairman of the Medical and Scientific Steering Committee of the Kidney Cancer Association.

Dr. Choueiri is interested in developing novel therapies and biomarkers in genitourinary malignancies and kidney cancer. His research also focuses on patterns and outcomes of urinary and prostate cancers, using large scale approaches such as meta-analyses and national databases. His work is funded by the American Society of Clinical Oncology, the Harvard Kidney Cancer SPORE and the National Cancer Institute. He has over 350 PubMed-listed publications and is the overall principal investigator of multiple phase I-III trials in kidney cancer.

# BIOGRAPHIES

## International Faculty



**Manuela Schmidinger**

Manuela Schmidinger is Professor of Medicine and specialized in Internal Medicine, Medical Oncology and Intensive Care Medicine. She is currently a Senior Physician in the Department of Oncology and Programme Director for metastatic RCC, leading the research programme in the field of kidney cancer and the care of patients with RCC.

Her research interests include prognostic factors and treatment in renal cell carcinoma, tyrosine kinase inhibitor-related side effects and strategies to achieve long-term survival in mRCC. Professor Schmidinger is the author or co-author of more than 90 articles in peer-reviewed journals, including *Annals of Oncology*, *British Journal of Cancer*, *Journal of Clinical Oncology*, *Leukaemia & Lymphoma* and *New England Journal of Medicine*. She is also co-author of the *European Guidelines for kidney cancer treatment* and the author or co-author of four books in the field of immunology and oncology, including a recent textbook on targeted agents in kidney cancer.



**Samra Turajlic**

Samra Turajlic completed her undergraduate studies at Oxford University and her clinical training at UCL medical school. She gained a PhD in 2013 from University of London (Institute of Cancer Research) in the field of melanoma genetics and targeted therapy resistance. In 2014 she was awarded a Cancer Research UK Clinician Scientist Fellowship to study cancer evolution at the Francis Crick Institute, London. She completed her training in medical oncology in 2015 and joined the Skin and Urology Units at the Royal Marsden Hospital as a Consultant Medical Oncologist. She divides her time between the clinic and the lab. She is the Chief Clinical Investigator of translational studies into melanoma (<http://tracex.co.uk/studies/melanoma/>) and kidney cancer (<http://tracex.co.uk/studies/renal/>). Her research goal is to improve an evolutionary understanding of cancer and the reasons for treatment success and failure. Her clinical research interest is in validating novel targets and therapies for kidney cancer and melanoma. She has received funding grants from Harry J Lloyd Trust, CRUK, RMH-ICR BRC and the Rosetrees Trust.

# KCRNC Organization

**KCRNC** KIDNEY CANCER RESEARCH  
NETWORK OF CANADA  
**RRCRC** RÉSEAU DE RECHERCHE SUR LE  
CANCER DU REIN DU CANADA



## Anil Kapoor, KCRNC Chair

Dr. Anil Kapoor is currently Professor of Surgery (Urology & Oncology) at McMaster University/ St. Joseph's Hospital in Hamilton, Ontario, Canada. He obtained his MD from Dalhousie University. He is a Fellow of the Royal College of Physicians and Surgeons of Canada and a Diplomate of American Board of Urology. He is certified by the American Society of Transplant Surgeons, having obtained post-graduate training from the Cleveland Clinic Foundation in Renal Transplantation, Renal-Vascular surgery, and GU Oncology.

Dr. Kapoor is current Head of the Genito-Urinary Oncology program at the Juravinski Cancer Centre, Co-Chair of the NCIC Kidney Cancer Disease Group, and Chair of the Kidney Cancer Research Network of Canada (KCRNC). He is also current Chair of the Medical Advisory Board (MAB) of Kidney Cancer Canada (KCC). He has published over 180 peer-reviewed papers, 5 book chapters and over 150 abstracts in the fields of genito-urinary oncology (prostate cancer and kidney cancer), kidney transplantation, and urologic laparoscopy. He is current Head of the Clinical Trials Group at the McMaster Institute of Urology (MIU) and established the Kidney Cancer Centre at McMaster University in 2009, and the Prostate Cancer Basic Science Research Collaborative in 2015.



## Ranjena Maloni, KCRNC Project Manager

[ranjena.maloni@uhnresearch.ca](mailto:ranjena.maloni@uhnresearch.ca)

Ms. Ranjena Maloni is currently the Project Manager for the Kidney Cancer Research Network of Canada (KCRNC) and the Project Manager for the Canadian Kidney Cancer information system (CKCis). She is a Certified Clinical Research Professional (CCRP) and completed a postgraduate diploma in Clinical Research at Humber College. She has a BSc(Hons) from Western University in Biology and Environmental Science.

Ranjena has spent the last 10 years working in clinical research in a variety of fields, including research in Alzheimer's and diabetes. The majority of her experience has been in uro-oncology at Princess Margaret Cancer Centre, where she was the Special Projects and Clinical Trials Team lead for a large prostate cancer research group. Ranjena has been invited to give talks on the project management of investigator-initiated clinical research across Canada and in the UK. She also sits on the Board of Directors for the Canadian Pulmonary Fibrosis Foundation.

Telephone: 647-290-9865 • Fax: 866-519-9253 • [www.kcrnc.ca](http://www.kcrnc.ca)

February 22-24, 2018 • Kingbridge Centre, King City, ON

# Notes

February 22-24, 2018 • Kingbridge Centre, King City, ON

# Notes

February 22-24, 2018 • Kingbridge Centre, King City, ON

# WE WOULD LIKE TO THANK OUR SPONSORS

## PLATINUM



## GOLD



## BRONZE PLUS



## BRONZE



## CONTRIBUTOR



This program is an accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, reviewed and approved by the Canadian Urological Association. Completion of this program enables participants to claim a maximum of 11 hours of credit.



Canadian Urological Association  
*The Voice of Urology in Canada*

[cua.org](http://cua.org)